| Abstract | In an open trial, tolerance and safety of cyclosporine A was studied in 14 patients with refractory juvenile rheumatoid arthritis (JRA). The doses varied from 4-15 mg/kg/day. Treatment lasted for greater than 12 months in 11 and 6 to 9 months in 3 patients. Eleven patients were withdrawn due to lack of efficacy (4) or side effects (7). A drop of greater than 2 g/l in hemoglobin and a marked rise in serum creatinine were the cause of withdrawal in 5 patients. The effect of cyclosporine on disease activity seemed to be mainly symptomatic and temporary. Probably, the dose should be kept below 5 mg/kg/day. Future controlled studies should be aware of a risk of aggravation of anemia in children treated with cyclosporine. |
| Authors | M Ostensen, H M Høyeraal, E Kåss
(Affiliation: Oslo Sanitetsforening Rheumatism Hospital, Norway.)
|
| Journal | The Journal of rheumatology
(J Rheumatol)
Vol. 15
Issue 10
Pg. 1536-8
(Oct 1988)
ISSN: 0315-162X CANADA |
| PMID | 3204600
(Publication Type: Journal Article)
|
| Chemical References |
|
| Topics |
- Administration, Oral
- Adolescent
- Anemia, Hypochromic
(chemically induced)
- Arthritis, Juvenile Rheumatoid
(blood, drug therapy)
- Child
- Child, Preschool
- Cyclosporins
(administration & dosage, adverse effects, blood)
- Drug Administration Schedule
- Female
- Humans
- Male
- Retrospective Studies
|
